Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 19, 2019
Inventiva completes a capital increase of € 8.2 million subscribed by leading US and European biotech investors
Daix (France), September 19th, 2019 – Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas ...
September 19, 2019
Compugen Presents Update on COM701 Phase 1 Study at 2019 IGCS
HOLON, Israel, Sept. 19, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced progress in its ongoing ...
September 19, 2019
Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference
MARINA DEL REY, Calif., Sept. 19, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics ...
September 19, 2019
Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
REDWOOD CITY, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...
September 19, 2019
Foamix Announces Enrollment of First Patient in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), today announced that the first patient has been enrolled in ...
September 19, 2019
Entera Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference
JERUSALEM, Israel and BOSTON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President ...
September 19, 2019
Motus GI to Present at the Ladenburg Thalmann Healthcare Conference
Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, ...
September 19, 2019
Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference
FLORHAM PARK, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs ...
September 19, 2019
BrainsWay Announces Further Leadership Transition to U.S.
JERUSALEM and HACKENSACK, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the ...
September 19, 2019
Genkyotex Announces First Half 2019 Results
ARCHAMPS, France, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR00013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, ...
September 18, 2019
ASIT biotech presents its 2019 half year results and provides further update on its clinical programs until end-2019
ASIT biotech (ASIT.BR) (ASIT.BR) (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough allergy immunotherapy products, ...
September 18, 2019
Saniona reports positive Tesomet Phase 2a clinical results in adolescent patients with Prader-Willi syndrome
Saniona (SANION.ST), a clinical stage biotech company focused on eating disorders and CNS, today announced that adolescent as well as adult patients with Prader-Willi syndrome ...
September 18, 2019
Emmaus Life Sciences Huddles Up with SCDAAMI to Host "Sideline Sickle Cell" Community Town Hall in Detroit
TORRANCE, Calif., Sept. 18, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that the company's ...
September 18, 2019
Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th
DUBLIN, Ireland, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for narcolepsy, today announced that Dr. Michael Thorpy, ...
September 18, 2019
aTyr Pharma to Participate in September Conferences
SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based ...
September 18, 2019
PolarityTE to Attend the 2019 Cantor Global Healthcare Conference
PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present at the 2019 Cantor Global ...
September 18, 2019
Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma
LEXINGTON, Mass., Sept. 18, 2019 /PRNewswire/ -- Pulmatrix, Inc. (PULM) today announced that the first patient has been dosed in the Phase 2 trial evaluating Pulmazole, an ...
September 18, 2019
Onxeo Announces Positive Intermediate Results From the First Part of the DRIIV-1b Study Evaluating AsiDNA™ in Combination With Chemotherapy
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting ...
September 18, 2019
OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance for SIRPα-Antagonist Monoclonal Antibody BI 765063
NANTES, France, Sept. 18, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announces today that the Company received a €5.4 million payment ...
September 17, 2019
Santhera to Present Long-Term Data with Puldysa® (Idebenone) in Duchenne Muscular Dystrophy at Upcoming Medical Congresses
Pratteln, Switzerland, September 17, 2019 – Santhera Pharmaceuticals (SANN.SW) will present data on the therapeutic effects of long-term treatment with Puldysa® (idebenone) in Duchenne muscular dystrophy ...
Page 7 of 169